POLYMATERIA
25.2.2021 11:54:08 CET | Business Wire | Press release
Polymateria, who in 2020 became the first company to evidence full biodegradation of plastic in the open environment, has today open-sourced data showing that its Biotransformation technology is recyclable as well as biodegradable.
Heralding a step forward in the shift to a more circular economy, polyethylene filmcontaining Polymateria’s Biotransformation technology has been shown to meet accepted industry protocol for recyclability through independent testing.
Polymateria’s technology demonstrates that the vision of a truly circular economy is possible. An economy where materials are reused or recycled as a matter of priority while allowing any items escaping the system to return to nature without causing any harm. By uniquely time-controlling when biodegradation will start, Polymateria’s technology allows time for recycling to take place before biodegradation is triggered.
Through open-sourcing its data, Polymateria invites other companies to work together to build a truly circular economy. The company is looking forward to working with plastic manufacturers, consumer brands and recyclers to unite the value chain and bring the circular economy vision to life.
Biodegradation of material containing Polymateria’s technology is verified by the British Standard Institution’s (BSI) new PAS 9017 standard for the Biodegradation of polyolefins in an open-air terrestrial environment which was launched in late 2020. The first of its kind, the standard sets a series of stringent pass/fail criteria ensuring full biodegradation with no microplastics or ecotoxicity left behind.
The open-sourced recyclability report from Impact Solutions can be found here .
Nial Dunne, CEO of Polymateria, said:
This is a good day for all those who believe in building a circular economy.
For too long, it has been assumed that biodegradable material cannot also be recycled. Our technology is changing perceptions. Products containing our technology should be recycled as a matter of priority, but any items escaping the system will return to nature at the right time without causing any harm.
As enablers of a circular economy, we invite the industry to join the growing number of partners working with us to bring a circular economy vision to life.
Dr Christopher Wallis, Polymateria SVP of Innovations, said:
I am pleased with the technical recyclability results achieved through the independent testing conducted by Impact Solutions. With these results, we can demonstrate that material containing our technology meets current industry protocol for mechanical recycling of polyolefins.
Dr Michail Kalloudis, Director of Polymer Science at Impact Solutions, said:
Our independent research clearly demonstrates that polyethele film containing Polymateria’s Biotransfromation masterbatch is recyclable within normal mechanical recycling streams. We tested the material stringently against recycling industry protocol.
Dr Simon Hepworth, Director of Enterprise at Imperial College London said:
We are delighted to see the progress being made by Polymateria, first at the White City Incubator and now within the Translation & Innovation Hub (I-HUB), joining a range of deep tech companies and remaining part of Imperial's entrepreneurial ecosystem. As a science-focused business developing technology to address global environmental challenges, we're proud to see them flourish and to continue our role in supporting Polymateria's efforts to build a circular economy.
Technical note:
- Polyethelene film containing Polymateria’s masterbatch technology was tested by Impact Solutions, UK. The report can be accessed here .
- Recyclability was tested and proven against the Recyclass “Recyclability Assessment Protocols for PE Films ” version 1.0 published on September 6th 2018.
About Polymateria
Polymateria’s mission is to advance science to help nature deal with the plastic pollution crisis. Born from, and now based at, Imperial College London, we’re the first company in the world to prove scientifically that you can take the most likely sources of fugitive or littered plastic and return them to nature without creating microplastics, harming the natural environment or interfering with recycling streams at scale.
The British Standards Institutions’s new BSI PAS 9017 standard ensures claims of biodegradability in the open environment can be properly verified for the first time according to independent pass/fail criteria. The Standard and Polymateria's technology were recently featured in National Geographic magazine: https://www.nationalgeographic.co.uk/environment-and-conservation/2020/11/new-self-destructing-plastic-has-helped-define-a-new-british
In 2020, Puma became the first international brand to incorporate Polymateria’s technology into its shopping bags: https://www.polymateria.com/wp-content/uploads/2020/07/10663-STim_Polymateria_26072020-A.pdf
Polymateria also has a partnership with international chemical giant Clariant (now Avient) to bring the technology to South-East Asia: https://www.clariant.com/en/Corporate/News/2019/10/Clariant-and-Polymateria-launch-partnership-to-bring-new-Biotransformation-technology-to-market-in-S
Pour Les Femmes, the ethical brand founded by actor/activitist Robin Wright and designer Karen Fowler, is the first apparel brand to introduce Polyamteria’s technology into its packaging: https://pourlesfemmes.com/blogs/blog
The company is proud to be a founding signatory of HRH The Prince of Wales’ Terra Carta (Earth Charter) established under the Sutainanble Markets Initiative.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005481/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
